AGO2 and colonic neoplasm: Our laboratory has previously used CRISPR/Cas9-mediated knockout cells deficient for the primary AGO variants AGO1, AGO2 and AGO3 to examine the scope of RISC-mediated regulation in the cytoplasm and nuclei of HCT116 colon cancer-derived cells (33,34).